![]() ^ "Endo buys Canada's Paladin to counter sliding sales".^ "Endo Health to Buy Specialty Drug Maker for $1.6 Billion"."Endo Health to Buy Paladin Labs for $1.6 Billion". Endo met that threshold by buying Paladin Labs, a Canadian drug manufacturer, for $1.6 billion in a deal that was finalized Feb. The company was able to legally reincorporate in Ireland only after completing a deal to buy a foreign-based company using at least 20 percent of its own stock. "Endo re-incorporates in Ireland to save millions in taxes" (Blog post). ^ Houlder, Vanessa Boland, Vincent Politi, James (29 April 2014).In 2021, New York Attorney General Letitia James filed a lawsuit against Endo and several other opioid manufacturers for their alleged contribution to the opioid epidemic in New York. It was the first time that the FDA had "taken steps to remove a currently marketed opioid pain medication from sale due to the public health consequences of abuse." Opana has been linked to outbreaks of HIV, hepatitis C and serious blood disorders. Food and Drug Administration (FDA) released a press statement in which it announced that it requested Endo to withdraw its opioid drug, oxymorphone hydrochloride (Opana ER), from the market. Its 10-K statement indicates that a majority of the company's US revenue in 2016 was derived from the sale of prescription pain killers, predominantly opioids. Opioids Įndo is one of the companies named in lawsuits by the states of Ohio, Missouri and Mississippi as responsible for the US opioid epidemic. On AugEndo International Plc filed for Chapter 11 bankruptcy protection after reaching a $6 billion deal with some of its creditors. In 2022, Endo's stock fell below $1 as the company faced restructuring of its $8 billion of debt. However, Teva prevailed in this acquisition with a substantially higher bid. In early 2014, Endo sought to acquire NuPathe, a speciality pharmaceutical developer, for $105 million. In 2018, Endo settled over 1,200 lawsuits related to its testosterone replacement therapy, Testim, and its undisclosed side effects. In 2015, Endo acquired the specialty generics and sterile injectables company Par Pharmaceutical for $8.05 billion. In October 2014, Endo said it would buy Auxilium Pharmaceuticals for $2.6 billion along with its testosterone replacement therapy products. they could afford to pay more to acquire U.S. In July 2015, The Wall Street Journal noted Endo was using Ireland's lower tax rate to acquire U.S.–based life sciences firms and relocate them to Ireland's tax regime (i.e. Įndo used the 2013 acquisition of Paladin Labs, and Canadian tax laws, to execute a corporate tax inversion to Ireland. In November 2013, Endo agreed to purchase Paladin Labs Inc for about $1.6 billion to gain access to the Canadian market as well as expand into emerging markets. The company entered the male hypogonadism market later in 2010 with Fortesta 2% gel. In 2009, Endo bought Indevus Pharmaceuticals to diversify into endocrinology and oncology. ![]() Setmelanotide is currently FDA-approved for certain genetic causes of obesity.ĭuring the meeting, the Endocrine Society released a scientific statement - also published in the Journal of Clinical Endocrinology & Metabolism - outlining the differences between normal aging and treatable conditions.See also: Corporation tax in the Republic of Ireland § Corporate tax inversionsĮndo was created as a result of a management buyout from DuPont Merck in 1997 led by Carol Ammon. "This impressive response adds to the evidence suggesting setmelanotide may provide a meaningful clinical benefit for patients with this disease who currently have no approved therapeutic options," said Roth in a statement. The most common cause of hypothalamic obesity was treatment of craniopharyngioma, followed by hypothalamic hamartoma, and juvenile pilocytic astrocytoma. The most commonly reported adverse events were nausea (69.2%), skin hyperpigmentation (38.5%), and vomiting (30.8%). All participants achieved a BMI reduction of at least 5%, while 10 of the 13 participants were able to achieve at least a 10% reduction. Most of this weight loss was achieved within the first 16 weeks of treatment, with an average BMI reduction of 16.8%.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |